HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Chongqing University Cancer Hospital

Status: Not yet enrolling

Conditions: Endometrial Cancer; HER2 Expression; Ovarian Cancer; Cervical Cancer

Treatments: Other: no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT06238284

CQ-HER2-GYN

Details and patient eligibility

About

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.

Enrollment: 300 estimated patients

Sex: Female

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with primary gynecological malignant tumor confirmed by histopathology
• Women aged 18-75
• The expected survival time is greater than 12 weeks
• KPS > 60, ECOG score is 0-2
• All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up

Exclusion criteria

• Pregnant and lactating women
• Suffering from other malignant tumors in the past 5 years
• Patients who are not suitable for this study according to the investigator's judgment

Trial design

300 participants in 3 patient groups

Cervical Cancer Group

Treatment:

Other: no intervention

Endometrial Cancer Group

Treatment:

Other: no intervention

Ovarian Cancer Group

Treatment:

Other: no intervention